Theranostics in nuclear medicine practice

References

• GridelliCDoes chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer?Lung Cancer200238Suppl 2S45S5012431829
   PubMedGoogle Scholar
• RichardsonJLMarksGLevineAThe influence of symptoms of disease and side effects of treatment on compliance with cancer therapyJ Clin Oncol1988611174617523183704
   PubMed Web of Science ®Google Scholar
• GerardSKCavalieriRRI-123 diagnostic thyroid tumor whole-body scanning with imaging at 6, 24, and 48 hoursClin Nucl Med20022711811805475
   PubMedGoogle Scholar
• AlzahraniASAlShaikhOTuliMAl-SugairAAlamawiRAl-RasheedMMDiagnostic value of recombinant human thyrotropin-stimulated 123I whole-body scintigraphy in the follow-up of patients with differentiated thyroid cancerClin Nucl Med201237322923422310247
   PubMedGoogle Scholar
• WalrandSHesseMRenaudLJamarFThe impact of image reconstruction bias on PET/CT 90Y dosimetry after radioembolizationJ Nucl Med2015563494495
   PubMedGoogle Scholar
• MüllerCZhernosekovKKösterUA unique matched quadruplet of terbium radioisotopes for PET and SPECT and for alpha- and beta-radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivativeJ Nucl Med201253121951195923139086
   PubMedGoogle Scholar
• SeidlinSMSiegelEYalowAAMelamedSAcute myeloid leukemia following prolonged iodine-131 therapy for metastatic thyroid carcinomaScience1956123320180080113324088
   PubMedGoogle Scholar
• AhmadzadehfarHTargeted therapy for metastatic prostate cancer with radionuclidesMohanRProstate Cancer – Leading-edge Diagnostic Procedures and Treatments InTech201610.5772/64016 Available from: https://www.intechopen.com/books/prostate-cancer-leading-edge-diagnostic-procedures-and-treatments/targeted-therapy-for-metastatic-prostate-cancer-with-radionuclidesAccessed August 23, 2017
   Google Scholar
• BaumRPKulkarniHRTHERANOSTICS: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy – the Bad Berka experienceTheranostics20122543744722768024
   PubMed Web of Science ®Google Scholar
• KwekkeboomDJde HerderWWKamBLTreatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3] octreotate: toxicity, efficacy, and survivalJ Clin Oncol200826132124213018445841
   PubMed Web of Science ®Google Scholar
• StrosbergJEl-HaddadGWolinENETTER-1 Trial InvestigatorsPhase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumorsN Engl J Med2017376212513528076709
   PubMed Web of Science ®Google Scholar
• YordanovaAMayerKBrossartPSafety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumourEur J Nucl Med Mol Imaging20174471207121428246882
   PubMed Web of Science ®Google Scholar
• AhmadzadehfarHEppardEKurpigSTherapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancerOncotarget2016711124771248826871285
   PubMedGoogle Scholar
• YordanovaABeckerAEppardEThe impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancerEur J Nucl Med Mol Imaging20174491473147928337529
   PubMedGoogle Scholar
• HolmanBLTumehSSSingle-photon emission computed tomography (SPECT): applications and potentialJAMA199026345615642403612
   PubMedGoogle Scholar
• EckelmanWCGibsonREThe design of site-directed radiopharmaceuticals for use in drug discoveryNuclear Imaging In Drug Discovery, Development, and ApprovalSpringer1993113134
   Google Scholar
• Kramer-MarekGCapalaJThe role of nuclear medicine in modern therapy of cancerTumour Biol201233362964022446937
   PubMedGoogle Scholar
• PillaiMRChakrabortySDasTVenkateshMRamamoorthyNProduction logistics of 177Lu for radionuclide therapyAppl Radiat Isot2003592–310911812941498
   PubMedGoogle Scholar
• AhmadzadehfarHBiersackHJEzziddinSRadioembolization of liver tumors with yttrium-90 microspheresSemin Nucl Med201040210512120113679
   PubMed Web of Science ®Google Scholar
• TeunissenJJMKwekkeboomDJde JongMEsserJPValkemaRKrenningEPEndocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapyBest Pract Res Clin Gastroenterol200519459561616183530
   PubMedGoogle Scholar
• HertzBDr. Saul Hertz (1905–1950) discovers the medical uses of radioactive iodine: the first targeted cancer therapyAhmadzadehfarHThyroid Cancer-Advances in Diagnosis and TherapyIntechopen20161
   Google Scholar
• KlingebielTBaderPBaresRTreatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot studyEur J Cancer1998349139814029849423
   PubMed Web of Science ®Google Scholar
• FrenchSDuBoisSGHornB131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastomaPediatr Blood Cancer201360587988423024113
   PubMedGoogle Scholar
• MatthayKKYanikGMessinaJPhase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastomaJ Clin Oncol20072591054106017369569
   PubMed Web of Science ®Google Scholar
• YanikGAVillablancaJGMarisJM131I-metaiodobenzyl-guanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II studyBiol Blood Marrow Transplant201521467368125639769
   PubMed Web of Science ®Google Scholar
• StoelbenEYordanovaAGossmannACarcinoids of the lungsBest Practice Onkologie20161152228 German [with English abstract]
   Google Scholar
• YordanovaAAhmadzadehfarHGonzalez-CarmonaMA step-by-step clinical approach for the management of neuroendocrine tumoursHorm Metab Res2017492778528099977
   PubMedGoogle Scholar
• FerdinandusJEppardEGartnerFPredictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617J Nucl Med201758231231927587707
   PubMed Web of Science ®Google Scholar
• MierWKratochwilCHasselJCRadiopharmaceutical therapy of patients with metastasized melanoma with the melanin-binding benzamide 131I-BA52J Nucl Med201455191424277756
   PubMedGoogle Scholar
• ZhangJLazarMAThe mechanism of action of thyroid hormonesAnnu Rev Physiol200062143946610845098
   PubMedGoogle Scholar
• PorterfieldSPHendrichCEThe role of thyroid hormones in prenatal and neonatal neurological development – current perspectivesEndocr Rev1993141941068491157
   PubMedGoogle Scholar
• BauerFKBarrettTFCassenBCScintigrams of the thyroid gland; the diagnosis of morphologic abnormalities with I131Calif Med195277638038213009497
   PubMedGoogle Scholar
• HänscheidHLassmannMDosimetrie bei der Radioiodtherapie benigner und maligner SchilddrüsenerkrankungenNuklearmediziner201235013036
   Google Scholar
• HertzBSchullerKSaul Hertz, MD (1905–1950): a pioneer in the use of radioactive iodineEndocrine Pract2010164713715
   PubMedGoogle Scholar
• HertzSRobertsARadioactive iodine as an indicator in thyroid physiology: V. The use of radioactive iodine in the differential diagnosis of two types of Graves’ diseaseJ Clin Invest1942211313216694888
   PubMedGoogle Scholar
• SeidlinSMRossmanIOshryESiegelERadioiodine therapy of metastases from carcinoma of the thyroid; a 6-year progress reportJ Clin Endocrinol Metab19499111122113715395978
   PubMedGoogle Scholar
• SeidlinSMRadioiodine in the treatment of metastatic thyroid carcinomaMed Clin North Am195236366368014928848
   PubMedGoogle Scholar
• LusterMClarkeSEDietleinMEuropean Association of Nuclear Medicine (EANM)Guidelines for radioiodine therapy of differentiated thyroid cancerEur J Nucl Med Mol Imaging200835101941195918670773
   PubMed Web of Science ®Google Scholar
• NakajoMShapiroBCoppJThe normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodobenzylguani-dine [I-131 MIBG] in man: evaluation by scintigraphyJ Nucl Med19832486726826135764
   PubMed Web of Science ®Google Scholar
• ShapiroBGrossMDRadiochemistry, biochemistry, and kinetics of 131I-metaiodobenzylguanidine (MIBG) and 123I-MIBG: clinical implications of the use of 123I-MIBGMed Pediatr Oncol19871541701773309602
   PubMedGoogle Scholar
• BombardieriEGiammarileFAktolunCEuropean Association for Nuclear Medicine131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imagingEur J Nucl Med Mol Imaging201037122436244620644928
   PubMedGoogle Scholar
• DecarolisBSchneiderCHeroBIodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison studyJ Clin Oncol201331794495123341514
   PubMedGoogle Scholar
• SchmidtMSimonTHeroBSchichaHBertholdFThe prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97Eur J Cancer200844111552155818424129
   PubMed Web of Science ®Google Scholar
• JacobsonAFDengHLombardJLessigHJBlackRR123 I-metaiodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysisJ Clin Endocrinol Metab20109562596260620392867
   PubMed Web of Science ®Google Scholar
• RufiniVFisherGAShulkinBLSissonJCShapiroBIodine-123-MIBG imaging of neuroblastoma: utility of SPECT and delayed imagingJ Nucl Med1996379146414688790194
   PubMedGoogle Scholar
• LeungAShapiroBHattnerRSpecificity of radioiodinated MIBG for neural crest tumors in childhoodJ Nucl Med1997389135213579293786
   PubMedGoogle Scholar
• OttRJTaitDFlowerMABabichJWLambrechtRMTreatment planning for 131I-mIBG radiotherapy of neural crest tumours using 124I-mIBG positron emission tomographyBr J Radiol1992657777877911393416
   PubMed Web of Science ®Google Scholar
• HuangSYBolchWELeeCPatient-specific dosimetry using pretherapy [124I]m-iodobenzylguanidine ([124I]mIBG) dynamic PET/CT imaging before [131I]mIBG targeted radionuclide therapy for neuroblastomaMol Imaging Biol201517228429425145966
   PubMed Web of Science ®Google Scholar
• ZhouMJDoralMYDuBoisSGVillablancaJGYanikGAMatthayKKDifferent outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG)Eur J Cancer201551162465247226254811
   PubMedGoogle Scholar
• PalmedoHRadionuclide therapy of bone metastasesBiersackHJFreemanLMClinical Nuclear MedicineBerlin, HeidelbergSpringer Berlin Heidelberg2007433442
   Google Scholar
• LiepeKKotzerkeJA comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastasesNucl Med Commun200728862363017625384
   PubMedGoogle Scholar
• PalmedoHManka-WaluchAAlbersPRepeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonateJ Clin Oncol200321152869287512885803
   PubMed Web of Science ®Google Scholar
• PalmedoHGuhlkeSBenderHDose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastasesEur J Nucl Med200027212313010755716
   PubMedGoogle Scholar
• BiersackHJPalmedoHAndrisAPalliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysisJ Nucl Med201152111721172621976530
   PubMed Web of Science ®Google Scholar
• MajkowskaANevesMAntunesIBilewiczAComplexes of low energy beta emitters 47Sc and 177Lu with zoledronic acid for bone pain therapyAppl Radiat Isot2009671111318929490
   PubMedGoogle Scholar
• KloppelGClassification and pathology of gastroenteropancreatic neuroendocrine neoplasmsEndocr Relat Cancer201118Suppl 1S1S1622005112
   PubMedGoogle Scholar
• KloppelGRindiGAnlaufMPerrenAKomminothPSite-specific biology and pathology of gastroenteropancreatic neuroendocrine tumorsVirchows Arch2007451Suppl 1S9S2717684761
   PubMedGoogle Scholar
• RindiGKloppelGCouvelardATNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading systemVirchows Arch2007451475776217674042
   PubMed Web of Science ®Google Scholar
• LambertsSWBakkerWHReubiJCKrenningEPTreatment with Sandostatin and in vivo localization of tumors with radiolabeled somatostatin analogsMetabolism1990399 Suppl 21521552169572
   PubMedGoogle Scholar
• LambertsSWReubiJCBakkerWHKrenningEPSomatostatin receptor imaging with 123I-Tyr3-OctreotideZ Gastroenterol199028Suppl 220211980773
   PubMedGoogle Scholar
• KrenningEPBakkerWHBreemanWALocalisation of endocrine-related tumours with radioiodinated analogue of somatostatinLancet1989186322422442563413
   PubMedGoogle Scholar
• PoeppelTDBinseIPetersennS68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumorsJ Nucl Med201152121864187022072704
   PubMedGoogle Scholar
• WildDSchmittJSGinjMDOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometalsEur J Nucl Med Mol Imaging200330101338134712937948
   PubMedGoogle Scholar
• GabrielMDecristoforoCKendlerD68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CTJ Nucl Med200748450851817401086
   PubMedGoogle Scholar
• HaugAAuernhammerCJWanglerBIntraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumoursEur J Nucl Med Mol Imaging200936576577019137293
   PubMedGoogle Scholar
• KayaniIBomanjiJBGrovesAFunctional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDGCancer2008112112447245518383518
   PubMed Web of Science ®Google Scholar
• ChitiAFantiSSavelliGComparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumoursEur J Nucl Med19982510139614039818279
   PubMedGoogle Scholar
• CimitanMBuonadonnaACannizzaroRSomatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical roleAnn Oncol20031471135114112853358
   PubMedGoogle Scholar
• SabetAEzziddinKPapeUFAccurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177) Lu-octreotateEur J Nucl Med Mol Imaging201441350551024196919
   PubMed Web of Science ®Google Scholar
• RomerASeilerDMarincekNSomatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumoursEur J Nucl Med Mol Imaging201441221422224085501
   PubMedGoogle Scholar
• WongFCKimEETherapeutic applications of radiopharmaceuticalsKimEEHandbook of Nuclear Medicine and Molecular Imaging: Principles and Clinical ApplicationsNew JerseyWorld Scientific2012401
   Google Scholar
• CwiklaJBSankowskiASekleckaNEfficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II studyAnn Oncol201021478779419833821
   PubMed Web of Science ®Google Scholar
• FerlayJSoerjomataramIDikshitRCancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012Int J Cancer20151365E359E38625220842
   PubMed Web of Science ®Google Scholar
• SonpavdeGPerimanPOBernoldDSunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapyAnn Oncol201021231932419633050
   PubMed Web of Science ®Google Scholar
• TolcherAWQuinnDIFerrariAA phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancerAnn Oncol201223496897321859898
   PubMed Web of Science ®Google Scholar
• GhoshAHestonWDWTumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancerJ Cell Biochem200491352853914755683
   PubMed Web of Science ®Google Scholar
• Mhawech-FaucegliaPZhangSTerraccianoLProstate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray techniqueHistopathology200750447248317448023
   PubMed Web of Science ®Google Scholar
• SantoniMScarpelliMMazzucchelliRTargeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promisesJ Biol Regul Homeost Agents201428455556325620167
   PubMed Web of Science ®Google Scholar
• SilverDAPellicerIFairWRHestonWDCordon-CardoCProstate-specific membrane antigen expression in normal and malignant human tissuesClin Cancer Res19973181859815541
   PubMed Web of Science ®Google Scholar
• Afshar-OromiehAAvtziEGieselFLThe diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancerEur J Nucl Med Mol Imaging201542219720925411132
   PubMed Web of Science ®Google Scholar
• HijaziSMellerBLeitsmannCPelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomographyProstate201575161934194026356236
   PubMedGoogle Scholar
• PereraMPapaNChristidisDSensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysisEur Urol201670692693727363387
   PubMed Web of Science ®Google Scholar
• Afshar-OromiehAHetzheimHKratochwilCThe theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesionsJ Nucl Med201556111697170526294298
   PubMed Web of Science ®Google Scholar
• Afshar-OromiehAHetzheimHKublerWRadiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timingEur J Nucl Med Mol Imaging20164391611162027260521
   PubMedGoogle Scholar
• RahbarKAhmadzadehfarHKratochwilCGerman multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patientsJ Nucl Med201758859027765862
   PubMed Web of Science ®Google Scholar
• RahbarKBodeAWeckesserMRadioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancerClin Nucl Med201641752252827088387
   PubMed Web of Science ®Google Scholar
• RahbarKSchmidtMHeinzelAResponse and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysisJ Nucl Med20165791334133827056618
   PubMed Web of Science ®Google Scholar
• AhmadzadehfarHRahbarKKurpigSEarly side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre studyEJNMMI Res20155111426099227
   PubMedGoogle Scholar
• BeckerAEppardEKuerpigSNephro- and hepatotoxicity after radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617J Nucl Med201657Suppl 21430
   Google Scholar
• ZimbelmannSEppardEHauserSHematotoxicity after radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617J Nucl Med201657Suppl 21429
   Google Scholar
• OkamotoSThiemeAAllmannJRadiation dosimetry for 177Lu-PSMA I&T in metastatic castration-resistant prostate cancer: absorbed dose in normal organs and tumor lesionsJ Nucl Med201758344545027660138
   PubMedGoogle Scholar
• KabasakalLAbuQbeitahMAygunAPre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancerEur J Nucl Med Mol Imaging201542131976198326227531
   PubMed Web of Science ®Google Scholar
• Rbah-VidalLVidalABillaudEMFTheranostic approach for metastatic pigmented melanoma using ICF15002, a multimodal radiotracer for both PET imaging and targeted radionuclide therapyNeoplasia2017191172727987437
   PubMedGoogle Scholar